2023 Life Science Primary Care Telehealth 
Lloyd Price
SEPTEMBER 2, 2023
Exec Summary: The European HealthTech M&A market is expected to remain active in 2023, albeit with some slowdown from the record-breaking levels seen in 2022. This trend is expected to continue in 2023, particularly in the areas of primary care, diagnostics, and hospital services.
Health Populi
JULY 7, 2023
See my Hot Points below, discussing my views on the morphing of health care real estate from Pill Hill and inpatient hospitals to the home and closer-to-home sites. In the 2023 Patient Consumer Survey report, the topline lesson is that “cost and location drive patient decisions, while service and comfort drive experience.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare IT News - Telehealth
MARCH 7, 2024
Then, three years ago, the health system expanded Nuance Dax to primary care and a number of specialties. In June 2023, Epic and Nuance expanded the integration to include GPT4-powered ambient documentation.
Health Populi
JULY 10, 2023
Today and tomorrow are Amazon Prime Days, 2023 style, when you can fetch bargains on lots of electronics (esp. 144 was also the deal Amazon first extended for a year’s introductory offer in February 2023 once the company’s acquisition of One Medical was completed.
Healthcare IT Today
OCTOBER 1, 2023
Surveys and Research Nearly 30% of telehealth visits result in an in-person follow-up within three weeks, and nearly half of patients who used telehealth only did it once, according to Trilliant Health’s latest report on trends shaping the healthcare economy.
Healthcare IT Today
JANUARY 4, 2023
As we head into 2023, we wanted to kick off the new year with a series of 2023 Health IT predictions. Continued consolidation in primary care There will continue to be consolidation in primary care. Optum Care is becoming a model for big companies. Ted Shannon, CFO at Strive Health.
Health Populi
JUNE 30, 2023
In 2023, the Humira biosimilar launch is seen as a “new milestone” for biosimilars in the U.S. Here is a de ep analysis from GoodRx on the launch of at least 9 Humira biosimilars for 2023, foretelling this one product alone could have a major impact on the overall cost of prescription drugs in the U.S.
Expert insights. Personalized for you.
64 
Let's personalize your content